Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DM
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
In patients with type 2 diabetes with inadequate glycemic control on diet and exercise after
6 weeks of treatment:
Objective: To assess the effects of co-administration of sitagliptin and metformin compared
to placebo on hepatic glucose production (HGP).
Hypothesis: After 6 weeks of treatment, the co-administration of sitagliptin and metformin
provides greater reduction in hepatic glucose production (HGP) compared to placebo.
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio